Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.
The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
- Cyramza: Colorectal cancer (CRC)
- Cyramza: Hepatocellular carcinoma (HCC)
- Cyramza: Bladder cancer
- Cyramza: Non-small cell lung cancer (NSCLC)
Cyramza: Gastric cancer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l9tzpz/cyramza?w=4